THE DEAL, AT A GLANCE
From the announcementProtagonist Therapeutics
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedProtagonist Therapeutics raised $200M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersProtagonist Therapeutics is using $200M in Growth Round financing to advance AI-designed peptide drugs for blood and GI diseases through late-stage clinical development.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Protagonist Therapeutics · Financing Record
Explore source-linked visual explanations for Protagonist Therapeutics. Unsupported claims are withheld while source review continues.
Record 947 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →